A
Alder Biopharmaceuticals
A biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics
About Alder Biopharmaceuticals
Alder BioPharmaceuticals, accessible via alderbio.com, is a dynamic startup focused on developing innovative treatments for brain diseases. The company operates in the biopharmaceutical sector, which involves creating drugs and therapies derived from biological sources to treat medical conditions. Alder BioPharmaceuticals primarily serves patients suffering from neurological disorders, including but not limited to migraines and other chronic brain conditions.
The market Alder BioPharmaceuticals operates in is highly specialized and competitive, targeting a global audience with a significant presence in regions such as North America, Europe, and Asia. The company’s business model revolves around extensive research and development (R&D) to discover new treatments, followed by clinical trials to ensure safety and efficacy. Once a treatment is approved by regulatory bodies, Alder BioPharmaceuticals moves to the commercialization phase, where it partners with healthcare providers and pharmaceutical distributors to bring its products to market.
Revenue generation for Alder BioPharmaceuticals primarily comes from the sale of its approved therapies. Additionally, the company may engage in licensing agreements, where it allows other pharmaceutical companies to use its patented technologies in exchange for royalties or upfront payments. This dual approach of direct sales and licensing helps diversify its income streams and mitigate risks associated with drug development.
Alder BioPharmaceuticals is committed to reducing the stigma surrounding brain diseases by sharing true patient stories through its platform, The Lundbeck Magazine. This initiative not only raises awareness but also fosters a supportive community for those affected by neurological conditions.
In summary, Alder BioPharmaceuticals is a forward-thinking company dedicated to improving the lives of patients with brain diseases through innovative treatments and a strong focus on research and development.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2004
- Headquarters
- Bothell, United States
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Sevin Rosen Funds
HIG Capital
H.I.G. HealthBridge
Series B and later5 investors entered at this stage
TPG
Delphi Ventures
TPG Biotech
Novo Ventures
Redmile Group
Source: Dealroom Talent Intelligence.
Global footprint
Patents
38 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alder Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alder Biopharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.